Table 1.
Patient characteristics
| Characteristics | N (%) |
|---|---|
| Age | |
| <40 | 1 (3) |
| 40–49 | 7 (20) |
| 50–59 | 17 (49) |
| 60–69 | 5 (14) |
| 70+ | 5 (14) |
| Race/ethnicity | |
| White | 32 (91) |
| Black | 2 (6) |
| American Indian/Alaska | 1 (3) |
| Performance status | |
| 0 | 19 (54) |
| 1 | 15 (43) |
| 2 | 1 (3) |
| Menopausal status at study entry | |
| Premenopausala | 4 (11) |
| Postmenopausal | 31 (89) |
| Lesion | |
| Visceral only | 8 (23) |
| Soft tissue/bone only | 15 (43) |
| Both | 12 (34) |
| Number of prior chemotherapy regimens for metastatic disease | |
| 0 | 19 (54) |
| 1 | 11 (31) |
| 2 | 5 (14) |
| Prior anthracycline | |
| Neoadjuvant/adjuvant | 18 (51) |
| Metastatic | 2 (6) |
| Prior taxane | |
| Neoadjuvant/adjuvant | 12 (34) |
| Metastatic | 3 (9) |
| Prior anthracycline and taxane ever (Note 12 in adjuvant) | 13 (37) |
| Number of prior hormone treatments | |
| 1 | 3 (9) |
| 2 | 9 (26) |
| ≥3 | 23 (66) |
| Prior tamoxifen | |
| Neoadjuvant/adjuvant | 18 (51) |
| Metastatic | 7 (20) |
| Both | 2 (6) |
| Prior anastrozole | |
| Neoadjuvant/adjuvant | 7 (20) |
| Metastatic | 5 (14) |
| Prior letrozole | |
| Neoadjuvant/adjuvant | 3 (9) |
| Metastatic | 22 (63) |
| Prior exemestane | |
| Neoadjuvant/adjuvant | 2 (6) |
| Metastatic | 15 (43) |
a
Given goserelin or leuprolide